PaperA randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal
References (28)
- et al.
Comparative study of the safety and immunogenicity of a DT-acellular pertussis and a DT-Whole-cell pertussis vaccine in Senegalese infants
European Journal of Clinical Microbiology and Infectious Diseases
(1996) - et al.
Reflections on the efficacy of pertussis vaccines
Review of Infectious Diseases
(1987) Placebo controlled trial of two acellular vaccines in Sweden—protective efficacy and adverse events
Lancet
(1988)Placebo controlled trial of two acellular vaccines in Sweden—protective efficacy and adverse events
Lancet
(1988)- et al.
Relative efficacy of two acellular pertussis vaccines during three years of passive surveillance
Vaccine
(1992) - et al.
Comparison of 13 acellular pertussis vaccines: overview and serologic responses
Pediatrics
(1995) - Preziosi, M.P., Wassilak, S.,Yam, A., Ndiaye, M., Simaga, A. and Simondon, F. Practical experiences in obtaining...
- et al.
Enrichment medium for the isolation of Bordetella
Journal of Clinical Microbiology
(1977) - et al.
Serological response to Bordetella pertussis
- et al.
Comparison of polymerase chain reaction, culture, and western immunoblot serology for diagnosis of Bordetella pertussis infection
Journal of Clinical Microbiology
(1993) Diagnostic polymerase chain reaction
Statistical methods in cancer research: Vol 2. The design and analysis of cohort studies
Modern Epidemiology
Cited by (224)
Epidemiology, prevention and control of pertussis in Spain: New vaccination strategies for lifelong protection
2022, Enfermedades Infecciosas y Microbiologia ClinicaCitation Excerpt :Several clinical studies have estimated efficacies of about 84–85% and 71–78% in the prevention of typical and mild pertussis, respectively, for acellular vaccines formulated with at least three bacterial antigens.40,41 Simondon and colleagues estimated the efficacy of a 2-component vaccine at 85%, which led to its approval within the regulatory framework and implementation in vaccination programmes.42 A single-component vaccine (PT) is still in use in northern Europe, with an efficacy of 71%.43
Dose-dependent effectiveness of acellular pertussis vaccine in infants: A population-based case-control study
2020, VaccineCitation Excerpt :We calculated effectiveness point estimates of 42.1% after the first dose of aPV, increasing with each dose of the primary series (83.9% after 2, 98.2% after 3, and 100% after 4 doses). These findings are in agreement with previous observational studies which have consistently shown approximately 50% protection against pertussis in infancy following a first dose of either wPV or aPV, and at least 80% protection after 2 doses [3,7,15–20]. As the evidence is consistent with incremental protection after each additional dose, it is essential to complete recommended doses in a timely fashion to achieve optimal protection conferred by pertussis vaccine.
Pertussis vaccines and protective immunity
2019, Current Opinion in ImmunologyWill we have new pertussis vaccines?
2018, Vaccine
- †
Present address: Unité de Recherche sur les Maladies Infectieuses et Parasitaires, Centre ORSTOM de Montpellier, 34032 Montpellier, France.